What practicing pathologists and oncologists should know about the new computational pathology‐based companion diagnostic tools
The Journal of Pathology · 2026-06 · 269 (2) · 143-148
DOI: 10.1002/path.70045 ↗At a glance
Übersichtsarbeit in The Journal of Pathology, published online on 2026-02-25. Written by Diana Montezuma and 11 co-authors. Institution: European Society of Digital and Integrative Pathology (ESDIP), Lisbon, Portugal. Major MEDLINE topics: Pathologists, Neoplasms, Oncologists, Diagnosis, Computer-Assisted. Cited 3 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Society of Digital and Integrative Pathology.
Abstract (original language)
The integration of artificial intelligence into pathology is transforming the assessment of histological and immunohistochemical (IHC) slides, offering opportunities to reduce variability and streamline diagnostics. In practical terms, most available tools and research models emulate the diagnostic capabilities of pathologists by detecting, grading, and classifying tumours and other diseases. More recent applications have moved beyond mimicry, aiming to predict established biomarkers, such as microsatellite instability or IHC‐based markers, and to tackle even more ambitious tasks, such as directly predicting patient prognosis from H&E whole slide images. Remarkably, novel computational tools are now being designed as companion diagnostic assays, linking the automated evaluation of specific IHC biomarkers to the prediction of response to specific drugs, potentially marking a new chapter in the evolution of digital and computational pathology. The TROPION‐PanTumor01 trial recently demonstrated the superiority of a supervised machine learning model (termed the quantitative continuous score [QCS] by the vendor) in assessing TROP2 IHC compared with human scoring, promising better stratification of patients with non‐small cell lung cancer for treatment with datopotamab deruxtecan. The same approach has shown promise in refining HER2 (human epidermal growth factor receptor 2) and PD‐L1 (programmed death‐ligand 1) evaluations, revealing patient subgroups that may benefit from targeted therapies. Moreover, other similar approaches are progressively reaching the market, posing significant opportunities and challenges for clinicians involved in the care of patients with cancer. This Perspective is promoted by the European Society of Digital and Integrative Pathology (ESDIP, founded in 2016, and having long‐standing experience in computational pathology, esdipath.org ) and the European Interdisciplinary Society of Artificial Intelligence for Cancer Research (ESAC, a recently established initiative, founded in 2024, esac-network.eu ), both bringing together clinicians, engineers and other professionals dedicated to the development and clinical translation of computational approaches aimed at improving patient care. It aims to provide an informed overview of novel computational pathology companion diagnostic tools, with a particular focus on the background that practicing pathologists and oncologists need to have with these tools, when transitioning from research to clinical practice, irrespective of their prior familiarity with computational approaches. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- European Society of Digital and Integrative Pathology (ESDIP), Lisbon, Portugal.
- Research & Development Unit, IMP Diagnostics, Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP), Portuguese Oncology Institute of Porto, Comprehensive Cancer Center Raquel Seruca (Porto.CCC) & CI-IPOP@RISE (Health Research Network), Porto…
- Computational Pathology Group, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Institute of Tissue Medicine and Pathology (ITMP), University of Bern, Bern, Switzerland.
- Department of Digital Medicine, University of Bern, Bern, Switzerland.
ORCID profiles: Diana Montezuma, Sara P Oliveira, Inti Zlobec, Nadieh Khalili, Jordi Temprana-Salvador, Sabine Leh, David Ameisen, Mircea-Sebastian Șerbănescu, Arsela Prelaj, Jakob Nikolas Kather, Norman Zerbe, Vincenzo L'Imperio
Funding
- European Society of Digital and Integrative Pathology
Cite
APA
Montezuma, D., Oliveira, S. P., Zlobec, I., Khalili, N., Temprana-Salvador, J., Leh, S., Ameisen, D., Șerbănescu, M. S., Prelaj, A., Kather, J. N., Zerbe, N., & L'Imperio, V. (2026). What practicing pathologists and oncologists should know about the new computational pathology‐based companion diagnostic tools. The Journal of Pathology, 269(2), 143-148. https://doi.org/10.1002/path.70045
Vancouver
Montezuma D, Oliveira SP, Zlobec I, Khalili N, Temprana-Salvador J, Leh S, et al. What practicing pathologists and oncologists should know about the new computational pathology‐based companion diagnostic tools. The Journal of Pathology. 2026;269(2):143-148. doi:10.1002/path.70045
BibTeX
@article{Montezuma2026,
author = {Montezuma, Diana and Oliveira, Sara P and Zlobec, Inti and Khalili, Nadieh and Temprana-Salvador, Jordi and Leh, Sabine and Ameisen, David and Șerbănescu, Mircea-Sebastian and Prelaj, Arsela and Kather, Jakob Nikolas and Zerbe, Norman and L'Imperio, Vincenzo},
title = {What practicing pathologists and oncologists should know about the new computational pathology‐based companion diagnostic tools},
journal = {The Journal of Pathology},
year = {2026},
volume = {269},
number = {2},
pages = {143--148},
doi = {10.1002/path.70045}
}
EUVIMED